American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia

Schünemann, 2014, Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise, CMAJ, 186, E123, 10.1503/cmaj.131237 Institute of Medicine Qaseem, 2012, Guidelines International Network: toward international standards for clinical practice guidelines, Ann Intern Med, 156, 525, 10.7326/0003-4819-156-7-201204030-00009 Schünemann, 2015, Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines, Ann Intern Med, 163, 548, 10.7326/M14-1885 Alonso-Coello, 2016, GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines, BMJ, 353, i2089, 10.1136/bmj.i2089 Alonso-Coello, 2016, GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction, BMJ, 353, i2016, 10.1136/bmj.i2016 Atkins, 2004, Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group, BMC Health Serv Res, 4, 38, 10.1186/1472-6963-4-38 Guyatt, 2011, GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J Clin Epidemiol, 64, 383, 10.1016/j.jclinepi.2010.04.026 Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD Schünemann, 2003, Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations, CMAJ, 169, 677 Schünemann, 2016, GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health, J Clin Epidemiol, 76, 89, 10.1016/j.jclinepi.2016.01.032 Amiral, 1992, Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia, Thromb Haemost, 68, 95, 10.1055/s-0038-1656329 Rice, 2004, Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient), Arch Intern Med, 164, 1961, 10.1001/archinte.164.18.1961 Martel, 2005, Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis, Blood, 106, 2710, 10.1182/blood-2005-04-1546 Smythe, 2007, The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital, Chest, 131, 1644, 10.1378/chest.06-2109 Warkentin, 2000, Impact of the patient population on the risk for heparin-induced thrombocytopenia, Blood, 96, 1703, 10.1182/blood.V96.5.1703 Warkentin, 1996, A 14-year study of heparin-induced thrombocytopenia, Am J Med, 101, 502, 10.1016/S0002-9343(96)00258-6 Nand, 1997, Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution, Am J Hematol, 56, 12, 10.1002/(SICI)1096-8652(199709)56:1<12::AID-AJH3>3.0.CO;2-5 Greinacher, 2005, Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients, Thromb Haemost, 94, 132 Greinacher, 2000, Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range, Blood, 96, 846, 10.1182/blood.V96.3.846 Rauova, 2005, Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia, Blood, 105, 131, 10.1182/blood-2004-04-1544 Warkentin, 1994, Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia, Blood, 84, 3691, 10.1182/blood.V84.11.3691.bloodjournal84113691 Pouplard, 2001, Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia, Blood, 97, 3300, 10.1182/blood.V97.10.3300 Kasthuri, 2012, PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI, Blood, 119, 5285, 10.1182/blood-2011-06-359430 Blank, 2002, Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells, Int Immunol, 14, 121, 10.1093/intimm/14.2.121 Xiao, 2008, Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion, Blood, 112, 1091, 10.1182/blood-2008-04-153288 Wallis, 1999, Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia, Am J Med, 106, 629, 10.1016/S0002-9343(99)00124-2 Lewis, 2001, Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia, Circulation, 103, 1838, 10.1161/01.CIR.103.14.1838 Chong, 2001, Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study, Thromb Haemost, 86, 1170, 10.1055/s-0037-1616046 Lubenow, 2005, Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3, J Thromb Haemost, 3, 2428, 10.1111/j.1538-7836.2005.01623.x Kuter, 2017, Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia, Am J Hematol, 92, 730, 10.1002/ajh.24759 Warkentin, 1995, Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin, N Engl J Med, 332, 1330, 10.1056/NEJM199505183322003 Warkentin, 2017, Fondaparinux for treatment of heparin-induced thrombocytopenia: too good to be true?, J Am Coll Cardiol, 70, 2649, 10.1016/j.jacc.2017.09.1098 Warkentin, 2011, Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE, Chest, 140, 366, 10.1378/chest.10-1599 Warkentin, 2006, Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia, Blood, 108, 2937, 10.1182/blood-2005-11-012450 Lubenow, 2010, The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia, Blood, 115, 1797, 10.1182/blood-2009-07-231506 Sanson, 1999, Safety of low-molecular-weight heparin in pregnancy: a systematic review, Thromb Haemost, 81, 668, 10.1055/s-0037-1614550 Obeng, 2015, Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system, J Pediatr, 166, 144, 10.1016/j.jpeds.2014.09.017 Warkentin, 2001, Temporal aspects of heparin-induced thrombocytopenia, N Engl J Med, 344, 1286, 10.1056/NEJM200104263441704 Pon, 2018, Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia, J Thromb Thrombolysis, 45, 536, 10.1007/s11239-018-1646-x Cuker, 2016, Management of the multiple phases of heparin-induced thrombocytopenia, Thromb Haemost, 116, 835 Cuker, 2012, Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis, Blood, 120, 4160, 10.1182/blood-2012-07-443051 Lo, 2009, Conflict of Interest in Medical Research, Education, and Practice Akl, 2014, Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study, J Clin Epidemiol, 67, 1222, 10.1016/j.jclinepi.2014.05.006 Guyatt, 2010, The vexing problem of guidelines and conflict of interest: a potential solution, Ann Intern Med, 152, 738, 10.7326/0003-4819-152-11-201006010-00254 Schünemann, 2009, An official American Thoracic Society Policy statement: managing conflict of interest in professional societies, Am J Respir Crit Care Med, 180, 564, 10.1164/rccm.200901-0126ST Brożek J , NowakA, KunstmanP, SchünemannHJ. GRADEpro Guideline Development Tool (GDT). Available at: www.guidelinedevelopment.org. Accessed 13 September 2018. Guyatt, 2011, GRADE guidelines: 2. Framing the question and deciding on important outcomes, J Clin Epidemiol, 64, 395, 10.1016/j.jclinepi.2010.09.012 Lubenow, 2002, Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin, Chest, 122, 37, 10.1378/chest.122.1.37 Nagler, 2016, Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis, Blood, 127, 546, 10.1182/blood-2015-07-661215 Sun, 2016, Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. A systematic review and meta-analysis, Thromb Haemost, 115, 1044, 10.1160/TH15-06-0523 Linkins Lewis, 2003, Argatroban anticoagulation in patients with heparin-induced thrombocytopenia, Arch Intern Med, 163, 1849, 10.1001/archinte.163.15.1849 Kang, 2012, Fondaparinux versus argatroban and danaparoid for the treatment of suspected or confirmed heparin-induced thrombocytopenia: A propensity score analysis [abstract], Blood, 120, 10.1182/blood.V120.21.2262.2262 Al-Rossaies, 2011, Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin, Int J Clin Pharm, 33, 997, 10.1007/s11096-011-9573-3 Magnani, 2006, Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004, Thromb Haemost, 95, 967, 10.1160/TH05-07-0489 Joseph, 2014, Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia, J Thromb Haemost, 12, 1044, 10.1111/jth.12592 Warkentin, 2017, Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review, Blood, 130, 1104, 10.1182/blood-2017-04-778993 Schindewolf, 2012, Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience, Thromb Res, 129, 17, 10.1016/j.thromres.2011.06.008 Greinacher, 1999, Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators, Circulation, 100, 587, 10.1161/01.CIR.100.6.587 Farner, 2001, A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia, Thromb Haemost, 85, 950, 10.1055/s-0037-1615946 Palatianos, 2004, Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost, J Thorac Cardiovasc Surg, 127, 548, 10.1016/j.jtcvs.2003.08.042 Palatianos, 2015, Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): an 11-year experience, Am J Hematol, 90, 608, 10.1002/ajh.24017 Jung, 2011, Safety of IVC filters with heparin-induced thrombocytopenia [abstract], Blood, 118, 10.1182/blood.V118.21.2225.2225 Hong, 2003, Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia, Blood, 101, 3049, 10.1182/blood-2002-05-1448 Mismetti, 2015, Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial, JAMA, 313, 1627, 10.1001/jama.2015.3780 Decousus, 1998, A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group, N Engl J Med, 338, 409, 10.1056/NEJM199802123380701 Warkentin, 1997, The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia, Ann Intern Med, 127, 804, 10.7326/0003-4819-127-9-199711010-00005 Srinivasan, 2004, Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia, Arch Intern Med, 164, 66, 10.1001/archinte.164.1.66 Lindhoff-Last, 2001, Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients, Clin Appl Thromb Hemost, 7, 300, 10.1177/107602960100700409 Goel, 2015, Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality, Blood, 125, 1470, 10.1182/blood-2014-10-605493 Refaai, 2010, Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia, J Thromb Haemost, 8, 1419, 10.1111/j.1538-7836.2010.03861.x Hopkins, 2008, Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature, Transfusion, 48, 2128, 10.1111/j.1537-2995.2008.01822.x Senzel, 2016, Negative heparin-induced thrombocytopenia test result after massive transfusion: believe it or not?, Am J Clin Pathol, 145, 717, 10.1093/ajcp/aqw031 Tardy, 1999, Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia, Thromb Haemost, 82, 1199, 10.1055/s-0037-1614355 Elalamy, 2009, Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia, Thromb Res, 124, 554, 10.1016/j.thromres.2009.04.002 van Es, 2014, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, 124, 1968, 10.1182/blood-2014-04-571232 Koster, 2000, Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients, J Cardiothorac Vasc Anesth, 14, 243, 10.1053/cr.2000.5861 Koster, 2007, Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial, Ann Thorac Surg, 83, 572, 10.1016/j.athoracsur.2006.09.038 Dyke, 2007, Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies, Ann Thorac Surg, 84, 836, 10.1016/j.athoracsur.2007.04.007 Czosnowski, 2008, Bivalirudin for patients with heparin-induced thrombocytopenia undergoing cardiovascular surgery, Ann Pharmacother, 42, 1304, 10.1345/aph.1K601 Smedira, 2006, Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study, J Thorac Cardiovasc Surg, 131, 686, 10.1016/j.jtcvs.2005.10.049 Riess, 2007, Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin-controlled pilot study, Thorac Cardiovasc Surg, 55, 233, 10.1055/s-2006-955956 Dyke, 2006, A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study, J Thorac Cardiovasc Surg, 131, 533, 10.1016/j.jtcvs.2005.09.057 Merry, 2004, Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery, Ann Thorac Surg, 77, 925, 10.1016/j.athoracsur.2003.09.061 Carrier, 2003, Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial, J Thorac Cardiovasc Surg, 125, 325, 10.1067/mtc.2003.103 Magnani, 1997, Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient, 487 Jaben, 2011, Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature, J Clin Apher, 26, 219, 10.1002/jca.20289 Huang Wadia, 2008, Intraoperative anticoagulation management during cardiac transplantation for a patient with heparin-induced thrombocytopenia and a left ventricular assist device, Tex Heart Inst J, 35, 62 Welsby, 2010, Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia, Anesth Analg, 110, 30, 10.1213/ANE.0b013e3181c3c1cd Aouifi, 2001, Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia, Ann Thorac Surg, 71, 678, 10.1016/S0003-4975(00)02022-1 Makhoul, 1987, Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery, Ann Thorac Surg, 43, 617, 10.1016/S0003-4975(10)60232-9 Koster, 2001, One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II, J Thorac Cardiovasc Surg, 122, 1254, 10.1067/mtc.2001.118271 Koster, 2001, Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban, Anesthesiology, 94, 245, 10.1097/00000542-200102000-00013 Olinger, 1984, Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation, J Thorac Cardiovasc Surg, 87, 673, 10.1016/S0022-5223(19)38447-8 Pötzsch, 2000, Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia, N Engl J Med, 343, 515, 10.1056/NEJM200008173430718 Selleng, 2008, Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation, Blood, 112, 4024, 10.1182/blood-2008-03-145243 Selleng, 2001, Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin, Ann Thorac Surg, 71, 1041, 10.1016/S0003-4975(00)02430-9 Warkentin, 2014, Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin, Blood, 123, 2485, 10.1182/blood-2013-10-533083 Davis, 2003, Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass, Ann Thorac Surg, 75, 264, 10.1016/S0003-4975(02)04299-6 Grocott, 1997, Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium, J Cardiothorac Vasc Anesth, 11, 875, 10.1016/S1053-0770(97)90124-5 Kappa, 1987, Carotid endarterectomy in patients with heparin-induced platelet activation: comparative efficacy of aspirin and iloprost (ZK36374), J Vasc Surg, 5, 693, 10.1016/0741-5214(87)90156-X Nuttall, 2003, Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series, Anesth Analg, 96, 344, 10.1213/00000539-200302000-00009 Warkentin, 2015, Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities, Blood, 125, 195, 10.1182/blood-2014-07-590844 Mahaffey, 2003, The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results, J Invasive Cardiol, 15, 611 Lewis, 2002, Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia, Catheter Cardiovasc Interv, 57, 177, 10.1002/ccd.10276 Lee, 2011, Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials, Int J Cardiol, 152, 369, 10.1016/j.ijcard.2010.08.007 Jang, 2004, Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study, J Thromb Thrombolysis, 18, 31, 10.1007/s11239-004-0171-2 Hale, 1998, Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia, Cathet Cardiovasc Diagn, 45, 318, 10.1002/(SICI)1097-0304(199811)45:3<318::AID-CCD23>3.0.CO;2-2 Link, 2009, Argatroban for anticoagulation in continuous renal replacement therapy, Crit Care Med, 37, 105, 10.1097/CCM.0b013e3181932394 Reddy, 2005, Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy, Ann Pharmacother, 39, 1601, 10.1345/aph.1G033 Matsuo, 1988, Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis, Thromb Res, 52, 165, 10.1016/0049-3848(88)90095-3 Yamamoto, 1996, Heparin-induced thrombocytopenia in hemodialysis patients, Am J Kidney Dis, 28, 82, 10.1016/S0272-6386(96)90134-1 Williamson, 2004, Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction, Pharmacotherapy, 24, 409, 10.1592/phco.24.4.409.33168 Matsuo, 1992, Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor, Br J Haematol, 82, 627, 10.1111/j.1365-2141.1992.tb06482.x Koide, 1995, Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis, Nephrol Dial Transplant, 10, 2137 Alatri, 2010, Treatment with argatroban in one haemodialysed patient with a heparin-induced thrombocytopenia and thrombotic complications, Intern Emerg Med, 5, 359, 10.1007/s11739-010-0357-x Athar, 2008, Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia, Am J Hematol, 83, 245, 10.1002/ajh.21072 Barginear, 2008, Heparin-induced thrombocytopenia complicating hemodialysis, Clin Appl Thromb Hemost, 14, 105, 10.1177/1076029607304405 de Pont, 2007, Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study, Crit Care, 11, R102, 10.1186/cc6119 Magnani, 2010, A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis, Thromb Res, 125, e171, 10.1016/j.thromres.2009.10.008 Zerbi, 2015, Use of fondaparinux for extracorporeal circuit anticoagulation in patients with heparin-induced thrombocytopenia type II (HIT II) on haemodiafiltration (HDF) [abstract], Nephrol Dial Transplant, 30, iii236, 10.1093/ndt/gfv179.22 Haase, 2005, Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II, Nephrol Dial Transplant, 20, 444, 10.1093/ndt/gfh544 Brown, 2013, Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type II and extracorporeal circuit thrombosis-a case report and review of the literature, Hemodial Int, 17, 444, 10.1111/hdi.12003 Al-Ali, 2016, Successful use of a bivalirudin treatment protocol to prevent extracorporeal thrombosis in ambulatory hemodialysis patients with heparin-induced thrombocytopenia, Hemodial Int, 20, 204, 10.1111/hdi.12379 Ng, 2015, First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia, Thromb Res, 135, 205, 10.1016/j.thromres.2014.06.005 Murray, 2004, A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease, Kidney Int, 66, 2446, 10.1111/j.1523-1755.2004.66022.x Polkinghorne, 2002, Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients, Am J Kidney Dis, 40, 990, 10.1053/ajkd.2002.36331 Henny, 1985, The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis, Thromb Haemost, 54, 460, 10.1055/s-0038-1657872 Liu, 2016, Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials, Crit Care, 20, 144, 10.1186/s13054-016-1299-0 Gorlin, 2011, Use of emergency medical identification in the paediatric haemophilia population: a national study, Haemophilia, 17, 215, 10.1111/j.1365-2516.2010.02415.x Watson, 2012, Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition, Br J Haematol, 159, 528 Smythe, 2016, Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism, J Thromb Thrombolysis, 41, 165, 10.1007/s11239-015-1315-2 Schünemann, 2017, GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT, J Clin Epidemiol, 81, 101, 10.1016/j.jclinepi.2016.09.009